Sandra Oršulić

21.4k total citations · 2 hit papers
95 papers, 6.8k citations indexed

About

Sandra Oršulić is a scholar working on Molecular Biology, Oncology and Reproductive Medicine. According to data from OpenAlex, Sandra Oršulić has authored 95 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Molecular Biology, 33 papers in Oncology and 23 papers in Reproductive Medicine. Recurrent topics in Sandra Oršulić's work include Ovarian cancer diagnosis and treatment (22 papers), Cancer Cells and Metastasis (13 papers) and Wnt/β-catenin signaling in development and cancer (9 papers). Sandra Oršulić is often cited by papers focused on Ovarian cancer diagnosis and treatment (22 papers), Cancer Cells and Metastasis (13 papers) and Wnt/β-catenin signaling in development and cancer (9 papers). Sandra Oršulić collaborates with scholars based in United States, China and Japan. Sandra Oršulić's co-authors include Mark Peifer, Eric J. Brown, Stephan Gasser, David H. Raulet, Dong‐Joo Cheon, Deyin Xing, Rolf Kemler, Beth Y. Karlan, Hermann Aberle and Otmar Huber and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Sandra Oršulić

92 papers receiving 6.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

2005 1.0k citations Sandra Oršulić et al. profile →
Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas

2024 52 citations Emily Ko, Jin-Fen Xiao et al. Nature Communications profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Sandra Oršulić	3.8k	2.3k	1.6k	1.2k	895	95	6.8k
Joan G. Jones	2.0k 0.5×	2.2k 1.0×	1.1k 0.7×	1.1k 0.9×	681 0.8×	70	4.9k
Viji Shridhar	4.5k 1.2×	1.4k 0.6×	431 0.3×	1.4k 1.1×	1.2k 1.4×	126	7.2k
Karin Milde‐Langosch	3.2k 0.9×	1.9k 0.8×	739 0.5×	1.8k 1.4×	284 0.3×	130	5.6k
Gerburg M. Wulf	5.6k 1.5×	3.8k 1.7×	2.1k 1.3×	965 0.8×	668 0.7×	100	7.8k
Viví Ann Flørenes	3.5k 0.9×	2.2k 1.0×	620 0.4×	1.0k 0.8×	603 0.7×	108	5.4k
Toyomasa Katagiri	6.1k 1.6×	2.3k 1.0×	1.2k 0.7×	1.6k 1.3×	876 1.0×	166	9.1k
Antonio Di Cristofano	6.7k 1.8×	2.1k 0.9×	1.2k 0.7×	1.5k 1.2×	631 0.7×	75	9.1k
Robert G. Ramsay	3.6k 0.9×	2.1k 0.9×	934 0.6×	939 0.8×	360 0.4×	176	6.5k
Masabumi Shibuya	4.6k 1.2×	1.7k 0.7×	990 0.6×	1.2k 1.0×	723 0.8×	77	6.6k
Gustavo Baldassarre	3.4k 0.9×	1.6k 0.7×	432 0.3×	1.8k 1.5×	581 0.6×	134	5.1k

Countries citing papers authored by Sandra Oršulić

Since Specialization

Citations

This map shows the geographic impact of Sandra Oršulić's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Oršulić with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Oršulić more than expected).

Fields of papers citing papers by Sandra Oršulić

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Oršulić. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Oršulić. The network helps show where Sandra Oršulić may publish in the future.

Co-authorship network of co-authors of Sandra Oršulić

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Oršulić. A scholar is included among the top collaborators of Sandra Oršulić based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Oršulić. Sandra Oršulić is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Seker-Polat, Fidan, et al.. (2025). High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancer. Journal of Clinical Investigation. 135(6). 1 indexed citations

Hernández, Vanessa, et al.. (2025). Novel PROTACs targeting tissue transglutaminase (TG2) suppress tumorigenicity of ovarian cancer cells. European Journal of Medicinal Chemistry. 301. 118228–118228.

Hu, Ye, Marcela Haro, Enes Taylan, et al.. (2024). INHBA(+) cancer-associated fibroblasts generate an immunosuppressive tumor microenvironment in ovarian cancer. npj Precision Oncology. 8(1). 35–35. 15 indexed citations

Xu, Alexander M., Marcela Haro, Ann E. Walts, et al.. (2024). Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma. Science Advances. 10(16). eadk8805–eadk8805. 14 indexed citations

Ko, Emily, Jin-Fen Xiao, Marco De Simone, et al.. (2024). Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas. Nature Communications. 15(1). 2498–2498. 52 indexed citations breakdown →

Zhang, Yaqi, Yinu Wang, Guangyuan Zhao, Sandra Oršulić, & Daniela Matei. (2023). Metabolic dependencies and targets in ovarian cancer. Pharmacology & Therapeutics. 245. 108413–108413. 32 indexed citations

Gertych, Arkadiusz, Ann E. Walts, Joshi John, et al.. (2022). Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers. Cells. 11(23). 3769–3769. 12 indexed citations

Fučíková, Jitka, An Coosemans, Sandra Oršulić, et al.. (2021). Immunological configuration of ovarian carcinoma: features and impact on disease outcome. Journal for ImmunoTherapy of Cancer. 9(10). e002873–e002873. 33 indexed citations

Yucer, Nur, Michael J. Workman, Alex Laperle, et al.. (2021). Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis. Cell Reports. 37(13). 110146–110146. 31 indexed citations

10.

Wang, Lei, Zohreh Amoozgar, Jing Huang, et al.. (2015). Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. Cancer Immunology Research. 3(9). 1030–1041. 132 indexed citations

11.

Righi, Elda, Satoshi Kashiwagi, J. P. Yuan, et al.. (2011). CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer. Cancer Research. 71(16). 5522–5534. 191 indexed citations

12.

Ibrahim, Nageatte, Lei He, Chee-Onn Leong, et al.. (2010). BRCA1-Associated Epigenetic Regulation of p73 Mediates an Effector Pathway for Chemosensitivity in Ovarian Carcinoma. Cancer Research. 70(18). 7155–7165. 41 indexed citations

13.

Goldberg, Michael S., Deyin Xing, Yin Ren, et al.. (2010). Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proceedings of the National Academy of Sciences. 108(2). 745–750. 83 indexed citations

14.

Wang, Runsheng, Jiangyong Miao, Esther Oliva, et al.. (2010). Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene. Cancer Research. 70(21). 8517–8525. 219 indexed citations

15.

Xing, Deyin, Mai Nitta, Lei He, et al.. (2009). A Role for BRCA1 in Uterine Leiomyosarcoma. Cancer Research. 69(21). 8231–8235. 47 indexed citations

16.

Daikoku, Takiko, Susanne Tranguch, Anindita Chakrabarty, et al.. (2007). Extracellular Signal-Regulated Kinase Is a Target of Cyclooxygenase-1-Peroxisome Proliferator-Activated Receptor-δ Signaling in Epithelial Ovarian Cancer. Cancer Research. 67(11). 5285–5292. 39 indexed citations

17.

Xing, Deyin & Sandra Oršulić. (2006). A Mouse Model for the Molecular Characterization of Brca1-Associated Ovarian Carcinoma. Cancer Research. 66(18). 8949–8953. 98 indexed citations

18.

Daikoku, Takiko, Dingzhi Wang, Susanne Tranguch, et al.. (2005). Cyclooxygenase-1 Is a Potential Target for Prevention and Treatment of Ovarian Epithelial Cancer. Cancer Research. 65(9). 3735–3744. 114 indexed citations

19.

Xing, Deyin & Sandra Oršulić. (2005). Modeling Resistance to Pathway-Targeted Therapy in Ovarian Cancer. Cell Cycle. 4(8). 1004–1006. 17 indexed citations

20.

Oršulić, Sandra & Mark Peifer. (1994). A method to stain nuclei of Drosophila for confocal microscopy.. PubMed. 16(3). 441–7. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact